Head to Head Survey: Arcadia Biosciences (RKDA) and Its Peers

Arcadia Biosciences (NASDAQ: RKDA) is one of 22 public companies in the “Agricultural chemicals” industry, but how does it contrast to its peers? We will compare Arcadia Biosciences to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, valuation and risk.

Insider & Institutional Ownership

31.5% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 35.7% of shares of all “Agricultural chemicals” companies are owned by institutional investors. 25.9% of Arcadia Biosciences shares are owned by insiders. Comparatively, 12.7% of shares of all “Agricultural chemicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Arcadia Biosciences and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Arcadia Biosciences $4.03 million -$15.70 million -1.46
Arcadia Biosciences Competitors $3.12 billion $272.01 million -4.95

Arcadia Biosciences’ peers have higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Arcadia Biosciences and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences 0 1 0 0 2.00
Arcadia Biosciences Competitors 183 596 654 38 2.37

Arcadia Biosciences currently has a consensus target price of $20.00, suggesting a potential upside of 100.00%. As a group, “Agricultural chemicals” companies have a potential upside of 12.65%. Given Arcadia Biosciences’ higher possible upside, equities analysts clearly believe Arcadia Biosciences is more favorable than its peers.

Profitability

This table compares Arcadia Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arcadia Biosciences -686.10% -259.46% -82.98%
Arcadia Biosciences Competitors -1,391.96% -20.06% -11.68%

Risk and Volatility

Arcadia Biosciences has a beta of -5.7, indicating that its share price is 670% less volatile than the S&P 500. Comparatively, Arcadia Biosciences’ peers have a beta of 0.53, indicating that their average share price is 47% less volatile than the S&P 500.

Summary

Arcadia Biosciences peers beat Arcadia Biosciences on 9 of the 13 factors compared.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaboration with Dow AgroSciences to develop and commercialize enhanced wheat quality trait. The company was founded in 2002 and is headquartered in Davis, California.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit